Company intelligence / Profile preview

Sumaya Verwaltungs

Tegernsee, Bavaria, Germany

Ownership: Private
Development stage: Other

Overview

Sumaya Verwaltungs is a German investment vehicle and family office for the Strüngmann family, notably Thomas and Andreas Strüngmann, the founders of Hexal. The firm is a prominent investor in the European life sciences and biotechnology sectors, providing long-term capital to innovative healthcare companies. Most famously, Sumaya and related Strüngmann entities were the seed investors and majority shareholders in BioNTech, the developer of the first authorized mRNA COVID-19 vaccine. The company focuses on transformative medical technologies, oncology, and infectious diseases through its extensive portfolio of biotech holdings.

Industry: Investors

Beyond the preview

Go deeper on Sumaya Verwaltungs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sumaya Verwaltungs.

Explore the full profile